KBC Group NV raised its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 6.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,191 shares of the biotechnology company’s stock after buying an additional 1,440 shares during the period. KBC Group NV’s holdings in United Therapeutics Corporation were worth $2,879,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of UTHR. JPMorgan Chase & Co. raised its position in United Therapeutics Corporation by 1.8% in the first quarter. JPMorgan Chase & Co. now owns 122,497 shares of the biotechnology company’s stock valued at $16,583,000 after buying an additional 2,223 shares during the period. Clarity Capital KCPS Ltd. acquired a new position in United Therapeutics Corporation during the first quarter valued at approximately $230,000. Argent Capital Management LLC raised its position in United Therapeutics Corporation by 2.4% in the first quarter. Argent Capital Management LLC now owns 2,530 shares of the biotechnology company’s stock valued at $343,000 after buying an additional 60 shares during the period. Greylin Investment Mangement Inc. raised its position in United Therapeutics Corporation by 42.3% in the second quarter. Greylin Investment Mangement Inc. now owns 2,975 shares of the biotechnology company’s stock valued at $386,000 after buying an additional 885 shares during the period. Finally, Nuveen Asset Management LLC raised its position in United Therapeutics Corporation by 222.1% in the first quarter. Nuveen Asset Management LLC now owns 64,507 shares of the biotechnology company’s stock valued at $8,733,000 after buying an additional 44,481 shares during the period.

Shares of United Therapeutics Corporation (NASDAQ UTHR) opened at 128.45 on Friday. The stock’s 50 day moving average is $130.18 and its 200 day moving average is $133.12. United Therapeutics Corporation has a 52 week low of $110.90 and a 52 week high of $169.89. The firm has a market cap of $5.58 billion, a P/E ratio of 14.90 and a beta of 1.51.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.61 by $4.86. The firm had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter last year, the business earned $4.42 EPS. On average, equities research analysts predict that United Therapeutics Corporation will post $10.09 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://theolympiareport.com/2017/08/27/united-therapeutics-corporation-uthr-position-increased-by-kbc-group-nv.html.

Several brokerages have issued reports on UTHR. ValuEngine lowered United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, June 2nd. BidaskClub raised United Therapeutics Corporation from a “sell” rating to a “hold” rating in a report on Friday, June 16th. Jefferies Group LLC reaffirmed a “sell” rating and set a $105.00 price objective on shares of United Therapeutics Corporation in a report on Thursday, June 8th. UBS AG reaffirmed a “sell” rating and set a $106.00 price objective on shares of United Therapeutics Corporation in a report on Thursday, July 6th. Finally, Zacks Investment Research lowered United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Six equities research analysts have rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $134.50.

In related news, CEO Martine A. Rothblatt sold 1,251 shares of the stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $125.02, for a total transaction of $156,400.02. Following the completion of the sale, the chief executive officer now owns 1,391 shares in the company, valued at approximately $173,902.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard Giltner sold 3,490 shares of the stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $131.12, for a total transaction of $457,608.80. The disclosure for this sale can be found here. Insiders have sold a total of 24,622 shares of company stock valued at $3,203,127 in the last quarter. 7.80% of the stock is currently owned by corporate insiders.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.